• Metadoro
  • Products
  • News and analysis

News and analysis

Check market insights shared by our community members
16.01.2025
Delta Is Taking Off To Update Its Highs

Delta Air Lines stock rose markedly by low double digits in the first ten days of the new year. The U.S. carrier has served more than 200 million customers in 2024, when it was also recognized by J.D. Power, a leading American data analytics and consumer intelligence company, for being No. 1 in First/Business and Premium Economy Passenger Satisfaction. Travelers became more willing to spend extra money for swanky seats when meeting a high level of service. Delta is just positioning itself as the nation's premium airline. And what's more important, its Christmas quarter's earnings reportedly surpassed average analyst pool projections. Driven by stronger travel demand, smart financial management and capacity discipline, Delta business provided last three-months' profit of $1.85 per share vs $1.28 at the same period one year ago, compared to $1.75 in consensus estimates. On January 10, the airline industry leader put its future profit levels within a range between $0.70 and $1 per share in the current quarter through the end of March, while analyst expectations were focused on $0.77 cents, according to data compiled by LSEG. The starting months of each year always perform worse. It is clear that all carriers made losses in the Covid years of 2020-2022, but Delta profits only recovered into a range from $0.25 to $0.45 in the first quarter of 2023 and 2024, respectively, but Q1 profit numbers varied from $0.75 to $0.96 even in the three blessed years before the pandemic. Delta added that it is forecasting annual earnings in excess of $7.35 a share, which would be the highest in its 100-year history, based on its planned revenue growth of 7% to 9% in the March quarter from a year ago. The announcement could be compared to an adjusted profit of $6.16 a share in 2024. The company happily breaks through ticket prices' rising effects, almost undisturbed by a reduction in airline seats in the domestic market, which was peculiar for most carriers. Thus, new expectations created a fertile ground for setting new price records, even though price movements on Delta charts look most convincing among its other American rivals.

By the way, Citigroup analysts freshly updated their outlook on Delta Air Lines shares to raise their price target to $80 from the previous $77, vs the actual range around $65 per share where the stock just came after a reasonable market correction from last week's and all-time highs. Citigroup said it has included factors like higher revenue per available seat mile, projections of slightly lower fuel prices, increased taxation, a minor rise in share count, and the incorporation of fourth-quarter 2024 results into their financial model, which has projected Delta's profit at $7.49 per share in 2024 and $8.72 in 2025. Delta shares are Buy-rated at Citi, and we agree with their positive estimates in general, while keeping in mind even better price goals somewhere between $82.5 and $85.

14.01.2025
Merck Becomes Interesting to Be Added to a Portfolio

Merck & Co (MRK) stocks have shown signs of becoming a compelling buy opportunity. Over the past six months, the stock has been in a downtrend, declining 29.8% to $94.50 per share. However, since mid-November, MRK has demonstrated a reversal of momentum, rebounding by 10.0% to reach $104.87 on December 5. Following a brief pullback and consolidation period, the stock has retested the downtrend resistance and appears poised to continue its upward trajectory.

With prices currently positioned to target $110.00, this represents a potential 9-10% upside from the present levels. Setting a stop-loss at $93.50 aligns with a prudent risk management strategy, providing protection against further downside while allowing for upside potential. The recent consolidation phase further supports the case for a breakout, making this an attractive moment to consider initiating or adding to a position in MRK.

09.01.2025
VeChain Is Suffering on Rising Borrowing Costs

VeChain (VET) has fallen 12.7% this week, trading at $0.0445, underperforming the broader cryptocurrency market. Bitcoin (BTC), the leading cryptocurrency, has declined by 5.6% to $93,220, with bearish momentum building as it approaches key support at $89,000-$91,000. This decline is largely attributed to tightening monetary conditions in the United States, which continue to weigh on risk assets. Investor confidence is further shaken by significant net outflows from spot BTC-ETFs, which lost $583 million on Wednesday, marking the second-largest single-day outflow on record.

If BTC falls below the critical support level of $89,000-$91,000, VeChain is likely to extend its losses, with prices potentially declining another 10% to $0.0400. A sustained drop in BTC could push VET even lower, towards $0.0300. Conversely, a strong rebound in BTC prices to the $100,000 level could drive VET back up to $0.0500, representing a recovery of approximately 12% from current levels.

14.01.2025
Tezos Is Seen Hodling above $1.200

Tezos (XTZ) has declined slightly by 0.2% this week, trading at $1.249, following Bitcoin’s (BTC) drop to $89,158, which triggered widespread altcoin sell-offs due to concerns of a potential further decline in BTC to $80,000. However, Bitcoin managed to hold above the critical support level at $89,000-$91,000, offering some relief to the broader crypto market.

Speculation about a shift in U.S. trade policy has provided additional support to crypto assets. Reports suggest the new U.S. administration may pursue a gradual increase in tariffs rather than an abrupt hike, which could help alleviate inflationary pressures and lead to a less aggressive monetary stance from the Federal Reserve.

This development is a positive signal for the cryptocurrency market and may help Tezos maintain its position above the key support level of $1.200.

23.01.2025
Ontology Is Sliding Towards $0.2000

Ontology (ONT) is down 2.3% this week, trading at $0.2176, in line with the broader crypto market where Bitcoin (BTC) has declined 2.0% to $101,632. While the new U.S. administration has made some strides toward fairer crypto regulation, Donald Trump has remained silent on the highly anticipated issue of adding Bitcoin to U.S. federal reserves.

Market speculation is rampant, with figures like BlackRock CEO Larry Fink suggesting Bitcoin could surge to $700,000 per coin if sovereign wealth funds begin accumulating. Other forecasts predict Bitcoin reaching $250,000 by year-end. While such projections could foster optimism, the lack of decisive action or announcements regarding U.S. crypto reserves is weighing heavily on the market.

For Ontology, the situation remains bearish. Having breached the critical support at $0.2500 last week, the token is now approaching the $0.2000 level. A failure to provide clear evidence or statements about U.S. federal crypto reserve plans could see ONT fall even further, breaching the $0.2000 mark and deepening its losses.

Rafael Quintana Martinez
Money Manager de alto rendimiento, con una sólida formación académica, profesional y de campo. Más de 9 años de experiencia especializada en el comercio de mercados financieros internacionales. La devoción, la fiabilidad, la responsabilidad y la ética impulsan mi vida. Actualmente me desempeño como Analista Senior para Metadoro. https://metadoro.com/es https://mx.investing.com/members/contributors/235587671/ https://es.tradingview.com/chart/EURUSD/rE9gVips/
Home Depot Long Trade on ATH S&P 500

The S&P 500 index is just a notch away from its all-time high record. On Thursday, the index reached 4803 points, with the previous all-time high of 4819 recorded on January 4, 2022. There is no doubt that a new record will be set. This is the right time to pick up strong stocks that could outperform the S&P 500 on a short distance. Home Depot (HD) stocks could be among such stocks. Its prices have added 3.3% to $356 since the beginning of the week and are sending upside signals to climb to $375 per share, where the resistance is located. I am planning to buy at current prices at $350-$357 with a target at $375. The stop-loss will be placed at $344.

3430
Rafael Quintana Martinez
Money Manager de alto rendimiento, con una sólida formación académica, profesional y de campo. Más de 9 años de experiencia especializada en el comercio de mercados financieros internacionales. La devoción, la fiabilidad, la responsabilidad y la ética impulsan mi vida. Actualmente me desempeño como Analista Senior para Metadoro. https://metadoro.com/es https://mx.investing.com/members/contributors/235587671/ https://es.tradingview.com/chart/EURUSD/rE9gVips/
Apecoin is Sinking

Apecoin (APE) is facing a decline, losing 3.3% to $1,347 this week. The altcoin experienced a more significant drop of 10.0% to $1,258 on Tuesday, but a subsequent strong recovery helped mitigate some of the losses. Apecoin, like many other altcoins, has been under ongoing pressure since the start of 2024. Additionally, the altcoin is dealing with its own negative news, as 15.6 million tokens (approximately $22 million) are set to be unblocked soon, leading to an increase in APE supply. The Bored Ape (BAYC) NFT collectibles are also reportedly underperforming.

From a technical perspective, the outlook for APE appears negative. The altcoin has moved below the uptrend and slipped beneath the support level at $1,500. This breach is considered a formal signal that prices might continue to decline, potentially reaching $1,000. However, this bearish scenario could be invalidated if prices manage to reclaim levels above $1,500 per token.

3320
Two Stocks to Skyrocket at the Start of 2024: NVIDIA

Shares of this artificial intelligence locomotive soared by 8.2% in the first two days of the week. The immediate focus was NVIDIA's leaked plan of launching its new chip, with an intention to distribute it in China. This would help to work legally surpassing the U.S .export restrictive rules. Mass production may start already in the Q2 2024r, two people familiar with the matter said. The launch was initially announced in November, but later it was delayed. New chip would be the most powerful of three China-focused items that the leader of this segment developed to comply with authorities. It has the potential to prevent squeezing market share in favour of Chinese domestic competitors. However, this was not the only good news from the company.

Nvidia also announced other components and software ahead of the Consumer Electronics Show in Las Vegas, including the GeForce RTX 40 SUPER series of graphics processors for video gamers. Besides, four Chinese electric vehicle brands, Li Auto, Great Wall Motor, Zeekr and Xiaomi confirmed they are ready to use Nvidia's DRIVE platform, which is the newest collection of technologies for autonomous driving and driver-assistance systems to perceive and respond to the environment. As an icing on the cake, JPMorgan shared the view that only NVIDIA's healthcare division has grown to a $1 billion+ business, listing computational demand for AI-related methods of drug discovery, genomics, patient diagnostics, as well as medical devices, wearables and robotics to add extra revenues. The latest price move has ensured a technical breakout well above the psychological resistance of $500 per share, as the next round figure of $600 becomes the new target for the near-term. Many analysts maintain Overweight ratings on NVIDIA stocks despite its market price more than tripled in 2023. Other companies boosted by the AI rally, including AMD, CrowdStrike, Qualcomm, Broadcom, Palo Alto Networks etc would also continue to benefit this winter from the industry trend led by NVIDIA.

3105
Two Stocks to Skyrocket at the Start of 2024: Merck

This January the oldest pharmaceutical and chemical concern in the world, which was founded in 1668 by Friedrich Jacob Merck, already updated its all-time highs at nearly $120 per share. Being one of the hits of 2022 due to its best selling Molnupiravir oral drug to inhibit the replication of coronavirus, the stock added about 10% to its market value since Christmas time.

Merck went all that way just in several days, supported by a purchase of cancer medicine developer Harpoon Therapeutics. The $680 million investment may substantially strengthen Merck's oncology portfolio with immunotherapies. Merck has made drastic efforts to guarantee future growth of its money streams after its blockbuster immunotherapy drug named Keytruda came close to losing key patents. Now the health segment bellwether got weapons to successfully confront biosimilar peers. Harpoon now has at least two immunotherapies in early stage of development for a type of lung cancer and for multiple myeloma. Immunotherapies are directing the patient's T cells to recognize and attack the cancer.

Merck's share price refused to fall after the dividend date on January 8, which was a good sign as well. It is scheduled to present its quarterly results on the first day of February and may continue to rise on expectations. The company set its new record in sales numbers at $16 billion in late October and may exceed this achievement. Its CEOs projected revenue growth of 5.3% YoY to earn $8.44 per share in 2024, compared to $7.66 in 2022, which was the best year in financial terms for Merck so far. The company sees its annual sales in 2023 within the range of $59.7 billion to $60.2 billion, which would be better than its initial projections of $58.6 billion to $59.6 billion.

Merck share price cleared the $100 epic technical resistance 15 months ago, and now it is aiming to conquer the next target area at $140-150. Increased sales of Molnupiravir in the winter season may contribute much to the ending quarter report after soaring by 47% in Q3, as the number of cases are growing once again, WHO said. Merck's anti-COVID drug was big in Japan, for example, while Merck doubled its annual forecast for the pill. Gardasil, which is proved to be an effective vaccine against cancers caused by the human papillomavirus, already provided sales of $2.59 billion in Q3 2023, up by 13% compared to the same period of 2022.

2696
186

Join our community

Share your professional and amateur observations, exchange experiences, anticipate developments

Category
All
Stocks
Crypto
Etf
Commodities
Indices
Currencies
Energies
Metals
Instruments
Author
All
Metadoro
Contributors